# A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)

> **NCT02279875** · PHASE2 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 113 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Linezolid
- **DRUG:** HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)

## Key facts

- **NCT ID:** NCT02279875
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-11-28
- **Final completion:** 2017-07
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279875, "A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02279875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*